New drug duo takes on deadly pancreatic cancer in early trial
NCT ID NCT07176702
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This phase 2 study tests whether adding a new antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) can shrink tumors better in people with HER2-positive pancreatic cancer that has spread. About 45 adults who have not had prior treatment for metastatic disease will take part. The main goal is to see how many patients respond, while also tracking side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Nanjing, 210008, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200233, China
Conditions
Explore the condition pages connected to this study.